PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: CHIKV study data published in Peer-Reviewed Journal, page-2

  1. 4,342 Posts.
    lightbulb Created with Sketch. 6875
    I'm glad they announced it officially...



    I liked this statement:

    “As joint pain and loss of limb strength are common aspects of CHIKV induced disease,
    these critical findings provide confidence in PPS as a potential world first CHIKV therapy”

    --Dr Lara Herrero

    Last edited by Mozzarc: 13/09/21
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.